Smartfin

Smartfin is a Belgian and UK growth equity firm with offices in Brussels and London, focused on B2B technology companies in Europe at Series B and growth stages. The firm grew out of a successful operating and entrepreneurial track record and applies that lens to its investment work. For physician AI and Health IT founders past Series A who are scaling commercially, Smartfin is one of the more credible European growth-equity options.

The thesis is European B2B technology, with active interest in healthcare software, AI/ML in healthcare, cybersecurity, and enterprise SaaS. Within healthcare, the team has backed Health IT and clinical software companies and is comfortable evaluating AI-driven products where the technology is embedded in a real commercial workflow. Pre-revenue, pure research-stage, or consumer-only companies are not a fit; the sweet spot is companies with real ARR, clear unit economics, and a path to scale across Europe and beyond.

Check sizes typically range from five to twenty-five million dollars at Series B and growth, with the firm willing to lead and price rounds and to follow on into later rounds. They tend to invest in companies with a few million to ten-plus million in ARR at entry, depending on growth and market. Geography is European with a strong Benelux and UK focus, and selective activity in DACH, the Nordics, and France.

The partner team mixes investing and operating backgrounds, supported by analysts and a platform function. Diligence is rigorous on revenue quality, sales motion, customer concentration, churn, and management depth. Decisions are committee-driven, and the firm tends to operate as a long-term partner with active board involvement post-investment.

The most reliable way in is through a portfolio CEO, a European growth-stage advisor, or a corporate finance contact already working with Smartfin. Cold inbound is read but converts less often than warm routes. When you reach out, lead with the metrics: ARR, growth, net retention, sales efficiency, and a clear view on how Smartfin’s capital and network unlock specific milestones. Bring a clean data room and a sober view on what the next eighteen to twenty-four months actually require. The right time to engage is one to two quarters before opening a Series B or growth round, with enough lead time for the team to dig in. Founders sub one million ARR, with weak retention, or pre-product market fit will not be a fit and should focus on seed and Series A specialists; founders with real European software businesses ready to scale will find Smartfin a serious partner.